Vildagliptin · Galvus

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 diabetes mellitus, monotherapy or with a sulfonylurea (marketed in Japan as Equa) (JP)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also approved (3)
JP
  • Type 2 diabetes mellitus, monotherapy or with a sulfonylurea (marketed in Japan as Equa)
Product first approved 2010pharmafile.com
EU
  • Type 2 diabetes mellitus in adults (monotherapy and combination therapy)
Product first approved 2007EMA
CN
  • Type 2 diabetes, add-on to metformin
thepharmaletter.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (71)
Type 2 Diabetes
NCT01871558 · Novartis Pharmaceuticals
2013-06 – 2015-02 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT01822548 · Azienda Ospedaliero-Universitaria di Parma
2010-10 – 2015-01 · Type 2 Diabetes
What this study did
NCT01811485 · Novartis Pharmaceuticals
2013-05 – 2014-02 · Diabetes Mellitus, Type 2
What this study did
NCT01582230 · Novartis Pharmaceuticals
2012-04 – 2013-05 · Type 2 Diabetes Mellitus
What this study did
NCT01497522 · Novartis Pharmaceuticals
2011-12 – 2013-02 · Diabetes Mellitus, Type 2
What this study did
NCT01357252 · Novartis Pharmaceuticals
2011-04 – 2013-01 · Type 2 Diabetes Mellitus
What this study did
NCT01257451 · Novartis Pharmaceuticals
2010-12 – 2012-03 · Type 2 Diabetes Mellitus
What this study did
NCT01159249 · Novartis Pharmaceuticals
2010-06 – 2012-01 · Type 2 Diabetes
What this study did
NCT01233622 · Novartis
2010-10 – 2011-11 · Type 2 Diabetes Mellitus
What this study did
NCT01224366 · Novartis
2010-09 – 2011-10 · Type 2 Diabetes Mellitus
What this study did
NCT00765830 · Novartis
2008-09 – 2011-04 · Diabetes Mellitus, Type 2, Renal Insufficiency
What this study did
NCT00770081 · Novartis
2008-09 – 2011-04 · Diabetes Mellitus, Type 2, Renal Insufficiency
What this study did
NCT01262586 · Novartis Pharmaceuticals
2010-11 – 2011-03 · Type II Diabetes Mellitus
What this study did
NCT00616811 · Novartis
2008-01 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
NCT00646542 · Novartis
2005-03 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
NCT01000688 · Radboud University Medical Center
2010-01 – 2010-10 · Type 2 Diabetes, Endothelial Dysfunction
What this study did
NCT00822211 · Novartis
2008-12 – 2009-12 · Type 2 Diabetes Mellitus
What this study did
NCT00651105 · Novartis
2008-02 – 2009-05 · Type-2 Diabetes, Healthy
What this study did
NCT00325429 · Novartis
started 2006-04 · Diabetes Mellitus, Type 2
What this study did
NCT00102466 · Novartis Pharmaceuticals
2005-01 – 2009-01 · Diabetes Mellitus, Type 2
What this study did
NCT00260156 · Novartis Pharmaceuticals
2005-11 – 2008-12 · Diabetes Mellitus, Type 2
What this study did
NCT00389415 · Novartis
started 2006-10 · Diabetes Mellitus, Type 2
What this study did
NCT00494884 · Novartis
2007-06 – 2008-07 · Diabetes Mellitus, Type 2
What this study did
NCT00468039 · Novartis
2007-03-06 – 2008-06-06 · Diabetes Mellitus, Type 2
What this study did
NCT00396357 · Novartis Pharmaceuticals
2006-10 – 2008-06 · Diabetes Mellitus, Type 2
What this study did
NCT00106340 · Novartis Pharmaceuticals
2005-03 – 2008-05-20 · Diabetes Mellitus, Type 2
What this study did
NCT00383578 · Novartis Pharmaceuticals
2006-09 – 2008-05 · Diabetes Mellitus, Type 2
What this study did
NCT00102388 · Novartis Pharmaceuticals
2005-01 – 2008-03 · Diabetes Mellitus, Type 2
What this study did
NCT00099853 · Novartis Pharmaceuticals
2004-05 – 2008-01 · Diabetes Mellitus, Type 2
What this study did
NCT00351884 · Novartis Pharmaceuticals
2006-05 – 2007-11 · Diabetes Mellitus, Type 2
What this study did
NCT00396071 · Novartis Pharmaceuticals
2006-10 – 2007-11 · Diabetes Mellitus, Type 2
What this study did
NCT00396227 · Novartis Pharmaceuticals
2006-10 – 2007-10 · Diabetes Mellitus, Type 2
What this study did
NCT00390520 · Novartis
2006-09 – 2007-09 · Diabetes Mellitus, Type 2
What this study did
NCT00368134 · Novartis
started 2006-08 · Diabetes Mellitus, Type 2
What this study did
NCT00351832 · Novartis
started 2006-06 · Diabetes Mellitus, Type 2
What this study did
NCT00138619 · Novartis
2004-11 – 2007-04 · Diabetes Mellitus, Type 2
What this study did
NCT00380445 · Novartis
2006-01 – 2007-04 · Diabetes Mellitus, Type 2
What this study did
NCT00237237 · Novartis
2005-10 – 2007-02 · Diabetes Mellitus, Type 2
What this study did
NCT00380380 · Novartis
2006-01 – 2006-11 · Diabetes Mellitus, Type 2
What this study did
NCT00110240 · Novartis Pharmaceuticals
2005-04 – 2006-10 · Diabetes Mellitus, Type 2
What this study did
NCT00138567 · Novartis
2005-01 – 2006-08 · Diabetes Mellitus, Type 2
What this study did
NCT00120536 · Novartis
2005-06 – 2006-07 · Diabetes Mellitus, Type 2
What this study did
NCT00138554 · Novartis
2004-11 – 2006-07 · Diabetes Mellitus, Type 2
What this study did
NCT00138593 · Novartis
2004-07 – 2006-07 · Diabetes Mellitus, Type 2
What this study did
NCT00101712 · Novartis Pharmaceuticals
2004-10 – 2006-05 · Diabetes Mellitus, Type 2
What this study did
NCT00138515 · Novartis
2004-11 – 2006-05 · Diabetes Mellitus, Type 2
What this study did
NCT00138541 · Novartis
2004-10 – 2006-04 · Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (5)
Type 2 Diabetes
NCT00860288 · Novartis Pharmaceuticals
2009-02 – 2011-03 · Diabetes Mellitus, Type 2
What this study did
NCT00821977 · Novartis
2008-11 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07811011 · Tanta University
2026-09-20 – 2027-03-30 · Poly Cystic Ovary Syndrome
What this study did
NCT06142656 · October 6 University
2023-11-25 – 2026-02-01 · Poly Cystic Ovary Syndrome
What this study did
NCT00936234 · Johann Wolfgang Goethe University Hospital
2009-07 – 2013-05 · SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
What this study did
Phase 2 (9)
Type 2 Diabetes
NCT00099957 · Novartis Pharmaceuticals
2003-09 – 2005-06 · Diabetes Mellitus, Type 2
What this study did
NCT00238498 · Novartis
2004-07 – 2005-06 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04761861 · Sadat City University
2021-02-16 – 2025-12-31 · Schizophrenia, Dyslipidemias
What this study did
NCT04300790 · MedSIR
2020-10-23 – 2025-03-16 · Breast Cancer
What this study did
NCT02803892 · Piemonti Lorenzo
2016-05 – 2019-03 · Diabetes Mellitus, Type 1
What this study did
NCT01018602 · Institut fur Diabetesforschung, Munich, Germany
2008-01 – 2015-06 · Insulin-dependent Gestational Diabetes
What this study did
NCT01452113 · University Hospital, Toulouse
2010-10 – 2013-03 · Diabetes Mellitus
What this study did
NCT00980356 · Medical University of Vienna
2009-09 – 2012-12 · Diabetes Mellitus
What this study did
NCT01346254 · Marcus Saemann
2009-12 – 2011-11 · Impaired Glucose Tolerance, Kidney Transplantation
What this study did
Phase 1/2 (3)
Type 2 Diabetes
NCT00633997 · Novartis
2008-02 – 2008-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04410341 · Sadat City University
2020-05-01 – 2024-12-01 · Major Depressive Disorder
What this study did
NCT00818571 · Novartis Pharmaceuticals
2008-12 – 2009-05 · Renal Impairment, Diabetes
What this study did
Phase 1 (12)
Type 2 Diabetes
NCT02749032 · Michael A. Nauck
2011-11 – 2014-03 · Type 2 Diabetes
What this study did
NCT01537120 · Merck Sharp & Dohme LLC
2011-12 – 2012-10 · Type 2 Diabetes Mellitus
What this study did
NCT00567047 · Novartis
2007-07 – 2009-01 · Type-2 Diabetes
What this study did
NCT00572650 · Novartis
2007-10 – 2007-11 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06248801 · Bio-innova Co., Ltd
2024-09-05 – 2024-10-15 · Healthy Subjects
What this study did
NCT06244407 · International Bio service
2024-05-23 – 2024-06-02 · Healthy Volunteer
What this study did
NCT06103747 · Reseach Laboratory of Clinical and Experimental Pharmacology
2023-02-21 – 2023-08-15 · Fed Conditions
What this study did
NCT06073600 · Reseach Laboratory of Clinical and Experimental Pharmacology
2022-05-20 – 2022-11-13 · Fed Conditions
What this study did
NCT02816970 · Genuine Research Center, Egypt
2014-02 – 2014-03 · Healthy
What this study did
Phase 4 (53)
Type 2 Diabetes
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT07077525 · Al-Azhar University
2023-06-01 – 2024-08-31 · Type 2 Diabetes
What this study did
NCT05359432 · Getz Pharma
2020-07-01 – 2021-08-18 · Type 2 Diabetes
What this study did
NCT04916093 · Beni-Suef University
2019-12-20 – 2020-12-15 · Diabetes Mellitus, Type 2
What this study did
NCT04485845 · Cairo University
2019-11-01 – 2020-09-30 · Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency
What this study did
NCT03563794 · The First Affiliated Hospital of Xiamen University
2018-06-10 – 2019-12-10 · T2DM
What this study did
NCT03693560 · Damanhour University
2018-10-08 – 2019-10-10 · Coronary Artery Disease, Diabetes Mellitus, Type 2
What this study did
NCT04654676 · University Malaysia Sarawak
2018-09-15 – 2019-08-31 · Diabetes Mellitus, Type 2
What this study did
NCT02853630 · India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
2013-12 – 2018-12 · TYpe 2 Diabetes Mellitus
What this study did
NCT03178591 · Chiang Mai University
2014-10 – 2018-07 · Diabetes Mellitus, Type 2, Ischemic Heart Disease
What this study did
NCT02089438 · Lund University
2014-05 – 2017-08 · Type 2 Diabetes
What this study did
NCT04237493 · University of Jordan
2017-02-14 – 2017-07-24 · Diabetes Mellitus, Type 2
What this study did
NCT02475070 · Lund University
2016-01 – 2017-06 · Type 2 Diabetes
What this study did
NCT02142309 · University of Campania Luigi Vanvitelli
2005-10 – 2017-01 · Type 2 Diabetes
What this study did
NCT01827280 · Rio de Janeiro State University
2013-04 – 2016-11 · 1- Microvascular Function, 2-oxidative Stress, 3-inflammation
What this study did
NCT02145611 · Dr. José Fernando Vilela-Martin MD PhD
2013-07 – 2016-05 · Type 2 Diabetes Mellitus, Hypertension, Endothelial Dysfunction
What this study did
NCT01604213 · Sheba Medical Center
2012-09 – 2016-04 · Type 2 Diabetes Mellitus, Ischemic Heart Disease
What this study did
NCT02007278 · Novartis Pharmaceuticals
2014-01-03 – 2016-02-22 · Type 2 Diabetes, Hypoglycemia
What this study did
NCT01472432 · University of Campania Luigi Vanvitelli
2011-05 – 2016-01 · Chronic Foot Ulcers
What this study did
NCT01766778 · Novartis Pharmaceuticals
2013-05-13 – 2015-10-22 · Type-2 Diabetes Mellitus
What this study did
NCT01679899 · Centro de Diabetes Curitiba Ltda
2012-12 – 2015-10 · Type 2 Diabetes Mellitus, Menopause, Osteoporosis, Osteopenia
What this study did
NCT01812122 · Seoul National University Hospital
2013-03 – 2015-10 · Diabetes Mellitus, Non-Insulin-Dependent
What this study did
NCT01582243 · Novartis Pharmaceuticals
2013-04 – 2015-09 · Diabetes Mellitus, Type 2
What this study did
NCT01867502 · Hospital de Clinicas de Porto Alegre
2014-04 – 2015-08 · Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring, Exercise
What this study did
NCT01862263 · Novartis Pharmaceuticals
2013-05 – 2015-07 · Type 2 Diabetes Mellitus
What this study did
NCT01757587 · Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
2011-12 – 2015-03 · Type 2 Diabetes
What this study did
NCT02002221 · Novartis Pharmaceuticals
2013-12 – 2015-02 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT01686932 · Novartis Pharmaceuticals
2012-11 – 2014-09 · Diabetes Mellitus Type 2
What this study did
NCT01910441 · Novartis Pharmaceuticals
2013-07 – 2014-09 · Type 2 Diabetes Mellitus
What this study did
NCT01219400 · Lund University
2012-01 – 2013-12 · Diabetes
What this study did
NCT01541956 · Novartis Pharmaceuticals
2012-02 – 2013-12 · Type 2 Diabetes
What this study did
NCT01649466 · Novartis Pharmaceuticals
2012-08 – 2013-10 · Type 2 Diabetes Mellitus
What this study did
NCT01758380 · Novartis Pharmaceuticals
2013-01 – 2013-09 · Type 2 Diabetes Mellitus
What this study did
NCT01356381 · Novartis Pharmaceuticals
2011-04 – 2013-08 · Type 2 Diabetes Mellitus
What this study did
NCT01099137 · Seoul National University Bundang Hospital
2010-01 – 2013-05 · Diabetes
What this study did
NCT01882907 · Pusan National University Hospital
2009-12 – 2013-03 · Type 2 Diabetes
What this study did
NCT01426737 · University of Zurich
2011-04 – 2013-01 · Type 2 Diabetes
What this study did
NCT01518101 · Novartis Pharmaceuticals
2012-01 – 2012-10 · Type 2 Diabetes
What this study did
NCT00894868 · Novartis Pharmaceuticals
2009-05 – 2012-08 · Congestive Heart Failure, Type II Diabetes Mellitus
What this study did
NCT01398592 · Novartis Pharmaceuticals
2011-06 – 2012-06 · Diabetes Mellitus Type 2
What this study did
NCT01238978 · Novartis
2010-10 – 2011-12 · Type 2 Diabetes Mellitus, Elderly
What this study did
NCT01196546 · Novartis
2010-03 – 2011-10 · Type 2 Diabetes Mellitus
What this study did
NCT01193296 · Novartis
2010-06 – 2011-06 · Type 2 Diabetes Mellitus
What this study did
NCT01309698 · Novartis Pharmaceuticals
2011-02 – 2011-04 · Type 2 Diabetes
What this study did
NCT01426802 · Novartis Pharmaceuticals
2010-10 – 2011-04 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT03253562 · MTI University
2017-02-01 – 2017-08-01 · Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients
What this study did
Early phase / not applicable (9)
Type 2 Diabetes
NCT06068686 · Damanhour University
2022-10-01 – 2024-12-01 · Type 2 Diabetes
What this study did
NCT06313008 · Damanhour University
2023-08-10 – 2024-10-10 · Coronary Artery Disease, Type 2 Diabetes
What this study did
NCT01703637 · Lin Liao
2012-10 – 2016-12 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06951334 · First Affiliated Hospital, Sun Yat-Sen University
2025-06-01 – 2026-12-31 · Parkinson's Disease
What this study did
NCT03500900 · Universitaire Ziekenhuizen KU Leuven
2016-03-01 – 2017-01-01 · Healthy
What this study did
NCT01083992 · Ziv Hospital
2012-04 – 2013-06 · Non-Alcoholic Fatty Liver Disease
What this study did
Used as active comparator (10)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Type 2 Diabetes
NCT05102149 · PegBio Co., Ltd.
2021-09-30 – 2025-04 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT00382096 · Novartis Pharmaceuticals
2006-09 – 2008-06-03 · Diabetes Mellitus, Type 2
What this study did
Phase 4 (4)
Type 2 Diabetes
NCT05366868 · National Center for Global Health and Medicine, Japan
2022-05-26 – 2027-03-31 · Diabetes Mellitus, Type 2
What this study did
NCT01528254 · Novartis Pharmaceuticals
2012-03-30 – 2019-04-04 · Type 2 Diabetes Mellitus
What this study did
NCT02999841 · Peking University
2016-03 – 2018-01 · Diabetes Mellitus, Type 2, Obesity
What this study did
NCT02832999 · Yaounde Central Hospital
2016-01 – 2016-12 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (2)
Type 2 Diabetes
NCT06889909 · Lahore General Hospital
2024-12-15 – 2025-06-15 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06913101 · PNS Hafeez - Naval Hospital
2024-11-15 – 2025-05-15 · Type 2 Diabetes Mellitus (T2DM)
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Type 2 Diabetes
NCT04841096 · Laboratorios Silanes S.A. de C.V.
2023-03-21 – 2024-05-15 · Type 2 Diabetes
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vildagliptin (Galvus): this drugPhase 3Small moleculeDPP-4Partial signal
NCT00099866: At the study end, significant HbA(1c) reductions from baseline were seen with both vildagliptin (-1.0 +/- 0.1%, P < 0.001) and metformin (-1.4 +/- 0.1%, P < 0.001) missed
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Omarigliptin (Marizev)
Phase 3(overall)
Small moleculeDPP-4
Reliable signal(overall)
NCT01755156: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A) (Baseline and Week 24): Omarigliptin (Phase A) -0.54 Percent (95% CI -0.69 to -0.4) vs Placebo to Omarigliptin (Phase A) 0 Percent (95% CI -0.14 to 0.15)
NCT01698775: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Baseline and Week 24): Omarigliptin (Phase A) -0.77 Percent (95% CI -1 to -0.54) vs Placebo to Omarigliptin (Phase A) -0.44 Percent (95% CI -0.67 to -0.21)
Prusogliptin (Shanzeping)Phase 3Small moleculeDPP-4Reliable signal
NCT04161430: HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo.
NCT04218734: Change in HbA1c at week 24: −0.70% (DBPR108 + metformin) vs −0.07% (placebo + metformin); upper limit of the 95% CI for the between-group difference was −0.39, below the 0% superiority margin (P < .001).
RetagliptinPhase 3Small moleculeDPP-4Partial signalNo reviewed efficacy summary in this indication
Teneligliptin (Tenelia)Phase 3Small moleculeDPP-4Partial signal
NCT01805830: Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL).
NCT01798238: Change in HbA1c at week 24, teneligliptin 20mg vs placebo: difference -0.94% (LS mean 95% CI -1.22, -0.65), p<0.001; fasting plasma glucose difference -1.21 mmol/L (95% CI -1.72, -0.70), p<0.001.
Trelagliptin (Zafatek)Phase 3Small moleculeDPP-4Weak signal
NCT02512068: Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089)
NCT02324569: Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period) (End of the screening period (Week 0) and End of Treatment Period I (Up to Week 12)): Treatment Group I -0.56% ± 0.070 vs Treatment Group II 0.07% ± 0.067; p=<0.0001 (Treatment Group I vs Treatment Group II)
YogliptinPhase 3Small moleculeDPP-4Partial signalNo reviewed efficacy summary in this indication
Retagliptin / Metformin (Ruilintang)Phase 1Small moleculeDPP-4, AMPKPartial signalNo reviewed efficacy summary in this indication

Large race: only the 76 furthest-along competitors are listed; 75 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

9 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Galvus (Vildagliptin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicableParkinson&#39;s DiseaseNot yet recruiting
Est. primary completion 2026-12-31 · NCT06951334 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Phase 2/3Poly Cystic Ovary SyndromeNot yet recruiting
Est. primary completion 2027-03-20 · NCT07811011 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 3dmRecruiting
Est. primary completion 2028-12 · NCT03925701 · CT.gov ↗
What to watch

See the full readout calendar ↗